Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Myelodysplastic Syndromes
Related studies linked through entity extraction aliases.
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
- Status
- RECRUITING
- Phase
- PHASE2
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations
- Status
- UNKNOWN
- Phase
- PHASE2
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
- Status
- COMPLETED
- Phase
- N/A
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
- Status
- WITHDRAWN
- Phase
- PHASE2
GENOMED4ALL: Improving MDS Classification and Prognosis by AI
- Status
- UNKNOWN
- Phase
- N/A
Methods of T Cell Depletion Trial (MoTD)
- Status
- RECRUITING
- Phase
- PHASE2
Biocollection in MyeloDysplastic Syndrome (P-MDS)
- Status
- RECRUITING
- Phase
- NA
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
- Status
- COMPLETED
- Phase
- PHASE2
MBG453 in Lower Risk MDS
- Status
- TERMINATED
- Phase
- PHASE2
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
- Status
- TERMINATED
- Phase
- PHASE1
Interplay Between Immune and Metabolic Programs in Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- N/A
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
- Status
- TERMINATED
- Phase
- PHASE3
Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2